CN1535149B - 噻唑基酰胺类化合物的局部应用 - Google Patents

噻唑基酰胺类化合物的局部应用 Download PDF

Info

Publication number
CN1535149B
CN1535149B CN028125304A CN02812530A CN1535149B CN 1535149 B CN1535149 B CN 1535149B CN 028125304 A CN028125304 A CN 028125304A CN 02812530 A CN02812530 A CN 02812530A CN 1535149 B CN1535149 B CN 1535149B
Authority
CN
China
Prior art keywords
alkyl
group
acid
amino
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN028125304A
Other languages
English (en)
Chinese (zh)
Other versions
CN1535149A (zh
Inventor
U·贝茨
T·莱希
W·本德
R·费舍尔
M·亨德里克斯
G·克利曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aicuris GmbH and Co KG
Original Assignee
Bayer Healthcare AG
Aicuris GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG, Aicuris GmbH and Co KG filed Critical Bayer Healthcare AG
Publication of CN1535149A publication Critical patent/CN1535149A/zh
Application granted granted Critical
Publication of CN1535149B publication Critical patent/CN1535149B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
CN028125304A 2001-06-22 2002-06-10 噻唑基酰胺类化合物的局部应用 Expired - Lifetime CN1535149B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10129714A DE10129714A1 (de) 2001-06-22 2001-06-22 Topische Anwendung von Thiazolylamiden
DE10129714.9 2001-06-22
PCT/EP2002/006327 WO2003000259A1 (de) 2001-06-22 2002-06-10 Topische anwendung von thiazolylamiden

Publications (2)

Publication Number Publication Date
CN1535149A CN1535149A (zh) 2004-10-06
CN1535149B true CN1535149B (zh) 2012-06-06

Family

ID=7688817

Family Applications (1)

Application Number Title Priority Date Filing Date
CN028125304A Expired - Lifetime CN1535149B (zh) 2001-06-22 2002-06-10 噻唑基酰胺类化合物的局部应用

Country Status (17)

Country Link
US (1) US7883713B2 (https=)
EP (2) EP1629842B1 (https=)
JP (1) JP4342304B2 (https=)
KR (1) KR100899491B1 (https=)
CN (1) CN1535149B (https=)
AT (2) ATE320253T1 (https=)
AU (1) AU2002345023B2 (https=)
BR (1) BRPI0210601B8 (https=)
CA (1) CA2451552C (https=)
DE (3) DE10129714A1 (https=)
DK (2) DK1629842T3 (https=)
ES (2) ES2341778T3 (https=)
IL (1) IL159258A0 (https=)
MX (1) MXPA03011518A (https=)
PL (1) PL208927B1 (https=)
PT (2) PT1401435E (https=)
WO (1) WO2003000259A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129715A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Thiazolylamide
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
CN103269593A (zh) * 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
JP6918823B2 (ja) 2016-04-06 2021-08-11 イノベーティブ モレキュールズ ゲーエムベーハーＩｎｎｏｖａｔｉｖｅ Ｍｏｌｅｃｕｌｅｓ Ｇｍｂｈ 抗ウイルス剤として有用なアミノチアゾール誘導体
LT3544976T (lt) 2016-11-28 2021-08-10 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
AR110251A1 (es) 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Una sal maleato de la base libre de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida, formulaciones farmacéuticas, métodos de fabricación y usos de la misma
AR110250A1 (es) * 2016-11-28 2019-03-13 Aicuris Anti Infective Cures Gmbh Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida
WO2019068817A1 (en) 2017-10-05 2019-04-11 Innovative Molecules Gmbh SUBSTITUTED THIAZOLEAN ENANTIOMERS AS ANTIVIRAL COMPOUNDS
EP3925595A1 (en) * 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
CA3168721A1 (en) * 2020-03-26 2021-09-30 Jessica Redmer Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047904A1 (de) * 1999-12-23 2001-07-05 Bayer Aktiengesellschaft Thiazolylamid-derivate
WO2001096874A1 (en) * 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA984848A (en) 1970-01-16 1976-03-02 Kurt H. Pilgram Herbicides
US3658830A (en) * 1970-01-16 1972-04-25 Shell Oil Co 5-(substituted mercapto sulfiny sulfonyl or sulfamoyl)
US3717651A (en) * 1970-04-20 1973-02-20 Shell Oil Co Thiazoles
US3847588A (en) * 1970-04-20 1974-11-12 Shell Oil Co Thiazoles herbicidal
GB2080682B (en) * 1980-07-30 1984-03-28 Ciba Geigy Ag Antiherpetically active lipstick
US4556560A (en) * 1983-01-24 1985-12-03 The Procter & Gamble Company Methods for the treatment and prophylaxis of diaper rash and diaper dermatitis
DE3319282A1 (de) * 1983-05-27 1984-11-29 Gödecke AG, 1000 Berlin Verwendung von adenosin bei der behandlung von herpes
ES2186811T3 (es) 1995-12-29 2003-05-16 Boehringer Ingelheim Pharma Derivados de feniltiazol con propiedades anti-virus herpes.
GB2311069A (en) 1996-03-14 1997-09-17 Merck & Co Inc Primase isolated from human cytomegalovirus (HCMV)
US5705344A (en) 1996-03-14 1998-01-06 Tularik, Inc. High-throughput screening assay for inhibitors of nucleic acid helicases
GB2311068A (en) 1996-03-14 1997-09-17 Merck & Co Inc Helicase isolated from human cytomegalovirus (HCMV)
CA2223032A1 (en) 1997-02-21 1998-08-21 Smithkline Beecham Corporation Use of hsv-1 ul-15 and vp5 in identifying anti-viral agents
DE19802437A1 (de) 1998-01-23 1999-07-29 Bayer Ag Verwendung von substituierten Sulfonamiden als anitvirale Mittel und neue Stoffe
AU3289299A (en) 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
NZ507032A (en) 1998-03-19 2003-06-30 Pharmacia & Upjohn 1,3,4-thiadiazoles useful for the treatment of herpes and cytomegalovirus infections
WO2000053591A1 (de) * 1999-03-08 2000-09-14 Bayer Aktiengesellschaft Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DE10129716A1 (de) 2001-06-22 2003-01-02 Bayer Ag Kombinationspräparate zur Herpes-Behandlung
DE10131128A1 (de) 2001-06-28 2003-01-16 Bayer Ag Sekundäre Sulfonamide
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001047904A1 (de) * 1999-12-23 2001-07-05 Bayer Aktiengesellschaft Thiazolylamid-derivate
WO2001096874A1 (en) * 2000-06-15 2001-12-20 Bayer Aktiengesellschaft Method for identifying compounds with anti-herpes activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KLEYMANN, GERALD ET AL.New helicase-primase inhibitors as drug candidates for thetreatment of herpes simplex disease..NATURE MEDICINE (NEW YORK, NY, UNITED STATES)8 4.2002,8(4),392-398.
KLEYMANN, GERALD ET AL.New helicase-primase inhibitors as drug candidates for thetreatment of herpes simplex disease..NATURE MEDICINE (NEW YORK, NY, UNITED STATES)8 4.2002,8(4),392-398. *

Also Published As

Publication number Publication date
AU2002345023B2 (en) 2007-07-12
EP1401435B1 (de) 2006-03-15
BR0210601A (pt) 2004-09-28
IL159258A0 (en) 2004-06-01
PL364378A1 (en) 2004-12-13
JP2004534818A (ja) 2004-11-18
CN1535149A (zh) 2004-10-06
BRPI0210601B1 (pt) 2016-08-23
WO2003000259A1 (de) 2003-01-03
US7883713B2 (en) 2011-02-08
ATE464047T1 (de) 2010-04-15
EP1401435A1 (de) 2004-03-31
EP1629842A1 (de) 2006-03-01
DK1401435T3 (da) 2006-07-17
MXPA03011518A (es) 2004-10-28
CA2451552A1 (en) 2003-01-03
DE50214378D1 (de) 2010-05-27
PT1401435E (pt) 2006-07-31
KR20040030689A (ko) 2004-04-09
ES2341778T3 (es) 2010-06-28
CA2451552C (en) 2011-11-08
KR100899491B1 (ko) 2009-05-26
JP4342304B2 (ja) 2009-10-14
PT1629842E (pt) 2010-05-10
ES2260449T3 (es) 2006-11-01
PL208927B1 (pl) 2011-06-30
ATE320253T1 (de) 2006-04-15
BRPI0210601B8 (pt) 2021-05-25
DK1629842T3 (da) 2010-08-02
EP1629842B1 (de) 2010-04-14
HK1069986A1 (en) 2005-06-10
US20040235917A1 (en) 2004-11-25
DE50206084D1 (de) 2006-05-11
DE10129714A1 (de) 2003-01-02

Similar Documents

Publication Publication Date Title
CN1535149B (zh) 噻唑基酰胺类化合物的局部应用
JP2021006593A (ja) ピリジルアミノ酢酸化合物を含む医薬製剤
AU2022271435A1 (en) Ophthalmic compositions
JP6886322B2 (ja) 眼科用組成物
JP2013536819A (ja) 緑内障および高眼圧症の処置のためのアデノシンａ１アゴニスト
JP7599838B2 (ja) エピナスチン又はその塩を含有する水性医薬組成物
JP2021095406A (ja) ピリジルアミノ酢酸化合物を含有する予防及び／又は治療剤
CN107108638A (zh) 哌啶基吡唑并嘧啶酮及其用途
JP2019073457A (ja) ホスアプレピタントを含有する医薬製剤
IL148292A (en) Stable preparations of lupoginone and other quinazolinone derivatives
TW201705956A (zh) 唑系抗真菌藥之對眼瞼皮膚的投與
DE10129716A1 (de) Kombinationspräparate zur Herpes-Behandlung
JPH11228404A (ja) 安定な水性点眼剤
CA2887878A1 (en) Use of pidotimod to treat psoriasis
CA2528493C (en) Medicinal composition containing triazole compound
JP2009256281A (ja) イソプロピルウノプロストン含有点眼剤組成物
US6329410B1 (en) Water-base liquid preparation
HK1069986B (en) Topical application of thiazolyl amides
JP2005015474A (ja) トリアゾール化合物を含有する医薬組成物
AU2014342010B2 (en) 3-{1-[5-chloro-2-(2-ethylbutoxy)benzyl]-5-methyl-1H-pyrazol-3-yl}propanoic acid in crystalline form and methods for use thereof
HK1031333A (en) Water-base liquid preparation
WO2016010130A1 (ja) 後眼部疾患の予防または治療剤
JPWO1999033464A1 (ja) 水性液剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1069986

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: AI LIMITED KUMARIS KG CO., LTD.

Free format text: FORMER OWNER: BAYER HEALTHCARE AG

Effective date: 20061013

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20061013

Address after: A German Wupo Seoul

Applicant after: AICURIS GmbH & Co.KG

Address before: Germany Leverkusen

Applicant before: Bayer Healthcare AG

C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: 10129714.9 2001.06.22 DE

Number: 23

Volume: 28

CI03 Correction of invention patent

Correction item: Priority

Correct: 10129714.9 2001.06.22 DE

Number: 23

Page: The title page

Volume: 28

ERR Gazette correction

Free format text: CORRECT: PRIORITY DATA; FROM: NONE TO: 10129714.9 2001.06.22 DE

RECT Rectification
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20120606